Study: Infliximab may be better than adalimumab for UC remission

10/16/2013 | MedPage Today (free registration)

A Canadian meta-analysis presented at the ACG Annual Scientific Meeting suggests infliximab may be more effective at inducing remission than adalimumab for patients with ulcerative colitis. Both anti-tumor necrosis factor drugs are FDA-approved for treating ulcerative colitis in patients who do not respond to or tolerate conventional therapy.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR